Smith & Nephew has reported third-quarter sales of $952 million, down from the $1.03 billion reported last year, according to a Bloomberg Businessweek report. The sales decline was attributed to revenue loss from its biologics and clinical therapies business line, which spun off and was branded Bioventus. Broken out by business line, sales from Smith & Nephew's knee products fell 1 percent, while its sports medicine products saw an 8 percent hike.
More Articles on Orthopedic Devices:
NeuroMetrix Signs Distribution Agreement for Pain Management Device
ConforMIS Moves Corporate Headquarters